Metraipolis › archive › dc_24377519ffd6

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line… — Europe PMC PMID:42047833

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42047833
DOI
10.1007/s00262-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-03T03:49:55.368Z
SHA-256 of the archived text
588e0d066c049bca5e96fd1f5ae64653a89a1ef1fd2772ba2441d8cbfb039f8b
Stable URL of this page
https://metraipolis.com/documento/dc_24377519ffd6

How to cite

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line… — Europe PMC PMID:42047833 — Europe PMC (en), https://europepmc.org/article/MED/42047833 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_24377519ffd6 (Metraipolis archive dc_24377519ffd6, sha256 588e0d066c049bca5e96fd1f5ae64653a89a1ef1fd2772ba2441d8cbfb039f8b)
BibTeX
@misc{dc24377519ffd6,
  title = {AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line… — Europe PMC PMID:42047833},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42047833},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_24377519ffd6; sha256 588e0d066c049bca5e96fd1f5ae64653a89a1ef1fd2772ba2441d8cbfb039f8b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42047833. Agents can read the archived copy with the MCP tool read_document.